There are currently 1902 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Early vs. Late Time-Restricted Eating in Adolescents With Obesity (EL TREA)
NCT05740254
Recruiting
Determine the effectiveness of how limiting the time you eat within an early or late eating window and fasting for remainder of the day will impact weight loss and body mass index (BMI).
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
10/19/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Pediatric Obesity, Time Restricted Feeding, Time Restricted Eating
Register for Updates
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: UCLA - JCCC Clinical Research Unit, Los Angeles, California
Conditions: Advanced Solid Tumor, Colorectal Cancer
Register for Updates
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
NCT04201873
Recruiting
This phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such as ATL-DC vaccine, may help the body build an effectiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Quan, Los Angeles, California
Conditions: Recurrent Glioblastoma
Register for Updates
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT04700488
Recruiting
The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: PDAC - Pancreatic Ductal Adenocarcinoma
Register for Updates
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NCT05566769
Recruiting
NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life. It has been co-designed with the help of patient advocacy groups, NMOSD patients and medical experts. It includes a smartphone-based application for patients, connected to a web portal developed for healthcare professionals (HCSPs). The patient application is composed of vision, walking, cognition, and dexterity e-active tests... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Neuromyelitis Optica
Register for Updates
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
NCT01429389
Recruiting
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Down Syndrome, Fetal Aneuploidy
Register for Updates
NEO100 and High-Grade Meningioma
NCT05023018
Recruiting
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times d... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/10/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Residual, Progressive or Recurrent Grade II or III Meningioma
Register for Updates
Impella RP Flex with Smart Assist
NCT06637644
Recruiting
To capture observational data of the Abiomed Impella RP Flex in a real-world setting.
Gender:
ALL
Ages:
All
Trial Updated:
10/09/2024
Locations: University of Southern California (Keck USC), Los Angeles, California
Conditions: Right Ventricular (RV) Dysfunction
Register for Updates
Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
NCT06067295
Recruiting
This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). By collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, diet, and quality of life) researchers hope to learn more about prostate cancer and ways to improve outcomes in the future.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Los Angeles County-USC Medical Center, Los Angeles, California +1 locations
Conditions: Prostate Carcinoma
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of California - Los Angeles, Los Angeles, California
Conditions: Giant Cell Tumor of Bone
Register for Updates
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
NCT05846516
Recruiting
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: * to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) * to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part) Participants will receive: i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: USC/Norris Comprehensive Center, Los Angeles, California +1 locations
Conditions: Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with bud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Southern California /ID# 254356, Los Angeles, California
Conditions: Solid Tumors
Register for Updates